NEJM: Expert comments on the opportunities and challenges of pan-PPAR agonists in the treatment of non-alcoholic steatohepatitis
Time of Update: 2021-11-04
On October 21, 2021, the New England Journal of Medicine (NEJM) published the results of a Phase 2b clinical trial of lanifibranor called NATIVE for the treatment of NASH .
NEJM: "Wrong" statins, common myalgia problems are not pharmacological side effects
Time of Update: 2021-02-24
patients taking statins and placebos experienced similar adverse reactions, according to a clinical trial recently published at the American Heart Association's (AHA) 2020 scientific meeting.
(Photo Source: Reference 1) Further statistics on adverse reactions found that 90 percent of the symptoms these patients experienced when taking statins also showed up when taking placebo pills.
Inner Mongolia announced 18 batches of non-conforming samples involving the total number of bacterite, aluminum residue and other indicators
Time of Update: 2021-02-11
Food Partners Network News Recently, the Inner Mongolia Autonomous Region Market Supervision And Administration announced the results of a food safety supervision sampling, extracted meat products, g
Domestic PD - (L) 1 McAb R & D panorama Hengrui and Xinda encounter obstacles in the competition of taking the lead in listing
Time of Update: 2018-04-09
Source: minenet on March 27, 2018-04-09, the news that "xindimab was dissuaded" came out of the circle of friends, causing a sudden uproar On February 14 this year, Hengrui pharmaceutical announced th